Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.62 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179795 | 1.00 | HRH1 (0.62) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL42066 | 1.00 | HRH1 (0.62) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL27928248 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| Hydrochloric Acid SCHEMBL4374172 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| Hydrochloric Acid SCHEMBL16032107 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| Bromide SCHEMBL28648396 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL7417534 | 0.88 | HRH1 (0.68) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL4281797 | 0.88 | HRH1 (0.68) | HRH1RIPK1LMNAAOC3HTR2A | |
| Cadaverine Tartrate SCHEMBL9851431 | 0.88 | HRH1 (0.50) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL7373079 | 0.86 | HRH1 (0.59) | HRH1RIPK1LMNAAOC3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765766-B1 | METHOD FOR PRODUCING ENANTIOMERS 3-HYDROXY-3-PHENYL-PROPYLAMINES | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-09-25 | — | — | EP | claimed |
| US-7294744-B2 | Process for manufacturing of enantiomerically pure 3-hydroxy-3-phenyl-propylamin | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-11-13 | — | — | US | claimed |
| US-20060009533-A1 | Process for manufacturing of enantiomerically pure 3-hydroxy-3-phenyl-propylamin | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-01-12 | — | — | US | claimed |
| US-20030096019-A1 | Methods of using norfluoxetine | SEPRACOR INC. | 2003-05-22 | — | — | US | claimed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-116217415-B | Method for synthesizing chiral 3-amino-1-phenylpropanol and chiral 3- (methylamino) -1-phenylpropanol | 武汉大学 | 2024-06-18 | — | — | CN | disclosed |
| US-20230295165-A1 | COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2023-09-21 | — | — | US | disclosed |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4188932-A1 | COMPOUNDS | The Provost, Fellows, Foundation Scholars and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth, (IE) | 2023-06-07 | — | — | EP | disclosed |
| US-20030096019-A1 | Methods of using norfluoxetine | SEPRACOR INC. | 2003-05-22 | — | — | US | disclosed |
| CN-1353719-A | Novel phosphorus-containing prodrugs | METABASIS THERAPEUTICS INC (US) | 2002-06-12 | — | — | CN | disclosed |
| EP-1210354-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | Metabasis Therapeutics, Inc. (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001018013-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | METABASIS THERAPEUTICS, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999032649-A1 | METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL 1,3-AMINOALCOHOLS | BIOCATALYTICS, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5250572-A | Treating depression | ELI LILLY AND COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096019-A1 | Methods of using norfluoxetine | NGF, TPH2, ALOX5 | HRH1 521/4885RIPK1 4867/4885LMNA 3632/4885 |
| US-20230295165-A1 | COMPOUNDS | NR3C1, NR3C2, CBR3 | HRH1 315/4885RIPK1 4199/4885LMNA 4284/4885 |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | HRH1 2308/4885RIPK1 3393/4885LMNA 565/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | HRH1 2486/4885RIPK1 3349/4885LMNA 566/4885 |
| US-20060009533-A1 | Process for manufacturing of enantiomerically pure 3-hydroxy-3-phenyl-propylamin | HPD, HNMT, PNMT | HRH1 16/4885RIPK1 2233/4885LMNA 3026/4885 |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS1, NOS3, NOS2 | HRH1 891/4885RIPK1 1647/4885LMNA 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.